Given that cyclin D1 is the most widely expressed cyclin D in different cell types and is most frequently implicated as a cancer driver in solid tumors (Baker and Reddy, 2012), we hypothesize that, in many clinical settings, activation of CDK6 may be enhanced by the assembly function of p21CIP1 or p27KIP1. Here, CDKN1A is linked to cancer.